ARST2531 (NCI CIRB)

Who Can Participate in the Study?

Age Group
Both

Study Details

Full Title
ARST2531: A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
Principal Investigator
Headshot of Jessica Muller Sun
Associate Professor of Pediatrics
Protocol Number
IRB: PRO00120899
NCT: NCT07466316
Phase
Phase III
ClinicalTrials.gov
Status
OPEN TO ACCRUAL